Journal article
Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis
- Abstract:
-
Aims
Angiopoietin-like protein 3 (ANGPTL3) and 4 (ANGPTL4) inhibit lipoprotein lipase (LPL) and represent emerging drug targets to lower circulating triglycerides and reduce cardiovascular risk. To investigate the molecular effects of genetic mimicry of ANGPTL3 and ANGPTL4 inhibition and compare them to the effects of genetic mimicry of LPL enhancement.
Methods and results
Associations of genetic variants in ANGPTL3 (rs11207977-T), ANGPTL4 ... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Novo Nordisk Fonden
More from this funder
Bibliographic Details
- Publisher:
- Oxford University Press Publisher's website
- Journal:
- European Heart Journal Journal website
- Volume:
- 42
- Issue:
- 12
- Pages:
- 1160–1169
- Publication date:
- 2020-12-22
- Acceptance date:
- 2020-11-16
- DOI:
- EISSN:
-
1522-9645
- ISSN:
-
0195-668X
- Pmid:
-
33351885
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1151399
- Local pid:
- pubs:1151399
- Deposit date:
- 2021-03-18
Terms of use
- Copyright holder:
- Wang et al.
- Copyright date:
- 2020
- Rights statement:
- ©2020 The Author(s). Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record